Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Researchers who want to dig deeper into peptide handling alongside their orders can also explore the step-by-step reconstitution guide, the peptide storage guide, and the peptide degradation tutorial for laboratory best practices
Frequency: Twice a week Benefits: Weight Loss Appetite Suppression Improves Energy Increases Metabolism Enhances Mood Helps regulate sleep Physician Consent for Treatment: A physician may contact you within 24 hours of purchase if additional information is needed
AOD 9604 trial history The most promising AOD 9604 data came from a Phase 2b trial involving 300 obese participants over 12 weeks
Watch a complete breakdown of its uses, side effects & more
The Drug Resistance Crisis Why New Options Matter Why We Urgently Need New Gonorrhea Medication Neisseria gonorrhoeae has earned its reputation as a superbug by systematically developing resistance to every antibiotic class introduced over the past century, making the December 2025 approval of zoliflodacin and gepotidacin a critical turning point in the battle against drug resistant gonorrhea. The Antibiotic Resistance Timeline 1940s: Penicillin became the first effective gonorrhea cure, providing near-100% success rates for two decades before widespread resistance emerged. 1970s-1980s: As penicillin resistance spread globally, healthcare providers shifted to tetracyclines and spectinomycin, only to see Neisseria gonorrhoeae treatment options narrow again within years. 1990s-2007: Fluoroquinolones like ciprofloxacin offered hope as oral gonorrhea antibiotics, but the CDC discontinued fluoroquinolone recommendations in 2007 after surveillance data revealed alarming resistance rates approaching 100% in some regions. 2010-present: Ceftriaxone injections combined with azithromycin became the last-resort standard for gonorrhea treatment, leaving virtually no backup options when resistance develops. The World Health Organization designated Neisseria gonorrhoeae as a high-priority pathogen in 2017 due to multidrug resistance affecting penicillin, tetracyclines, macrolides, sulphonamides, quinolones, and now emerging resistance to extended-spectrum cephalosporins
In animal models, this translated to meaningful reductions in fat mass without changes in food intake
